Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Moodys
Healthtrust
Queensland Health
Julphar
McKinsey

Generated: September 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BYETTA

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Byetta

Trial ID Title Status Sponsor Phase Summary
NCT00082381 Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin Completed Eli Lilly and Company Phase 3 This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082381 Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin Completed AstraZeneca Phase 3 This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed Eli Lilly and Company Phase 3 This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed AstraZeneca Phase 3 This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00097500 Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (LantusĀ® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
NCT00097500 Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (LantusĀ® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Byetta

Condition Name

Condition Name for Byetta
Intervention Trials
Type 2 Diabetes Mellitus 38
Type 2 Diabetes 16
Obesity 12
Diabetes Mellitus, Type 2 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Byetta
Intervention Trials
Diabetes Mellitus 74
Diabetes Mellitus, Type 2 65
Diabetes Mellitus, Type 1 7
Obesity 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Byetta

Trials by Country

Trials by Country for Byetta
Location Trials
United States 348
Canada 19
Mexico 15
United Kingdom 11
China 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Byetta
Location Trials
Texas 28
California 22
Florida 15
Washington 14
New York 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Byetta

Clinical Trial Phase

Clinical Trial Phase for Byetta
Clinical Trial Phase Trials
Phase 4 32
Phase 3 30
Phase 2/Phase 3 6
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Byetta
Clinical Trial Phase Trials
Completed 79
Recruiting 16
Unknown status 9
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Byetta

Sponsor Name

Sponsor Name for Byetta
Sponsor Trials
Eli Lilly and Company 46
AstraZeneca 41
Amylin Pharmaceuticals, LLC. 14
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Byetta
Sponsor Trials
Industry 119
Other 93
NIH 8
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Teva
Federal Trade Commission
Harvard Business School
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.